Shire, the Irish drugmaker, has settled patent lawsuits with Novartis’ Sandoz unit that was attempting to market a generic version of its attention deficit hyperactivity disorder drug (ADHD) Adderall XR – reported The New Yok Times.
As per the agreement, Sandoz will be able to sell an authorised generic version of the drug once it gets US FDA marketing approval and subsequently Shire will receive royalty payments. Both the companies are dropping all litigation, and Shire said that Sandoz has agreed to recognise two of the patents on Adderall XR as valid and enforceable.
Shire has already entered into similar settlements with Impax Laboratories and Barr Laboratories, a unit of Teva Pharmaceutical Industries. Shire has said that there are no other patent related challenges to generic versions of Adderall XR, and no generic versions have got US FDA approval, reported the news paper.